Treatment Registry

Company

NowPatient

NowPatient publishes oral semaglutide, brand semaglutide and brand tirzepatide, from $99 to $251.98 a month.

  • 3 programs
  • 3 molecules
  • 3 readings

Read from nowpatient.com on September 2, 2026. This page records what the company publishes. It is not a review and takes no position on the company.

Go to NowPatient

Visit NowPatient

We earn nothing from this link. NowPatient has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.

What it costs

Oral semaglutideOral tablet$99

first month, including the required fees on record · Wegovy Tablets, lowest dose (1.5mg), medication price; shipment/duties billed separately

Brand semaglutideInjection, pen$215.98

first month, including the required fees on record · Wegovy Injection, starting price

Brand tirzepatideInjection, pen$251.98

first month, including the required fees on record · Mounjaro, lowest dose (2.5mg/0.5mL), medication price; shipment/duties billed separately

Terms

MembershipOptional, $9.99 per month. The Core+ plan is NowPatient's premium membership tier, priced at £9.99 per month (UK) or $9.99 per month (US and Rest of the World), billed monthly. Core+ gives you the same access to all the features available through the Core plan, but now with unlimited usage of AI and health tracking tools. Free shipping is also included for treatments or prescription supplies.

Not yet checked: pharmacy, consultation fee and states.

Terms can differ between this company’s programs; each entry carries its own.

Programs

EntryProviderFormPer month
at its shortest term
Link
TR-0189NowPatientOral tablet$99
Wegovy Tablets, lowest dose (1.5mg), medication price; shipment/duties billed separately
Record
TR-0188NowPatientInjection, pen$215.98
Wegovy Injection, starting price
Record
TR-0187NowPatientInjection, pen$251.98
Mounjaro, lowest dose (2.5mg/0.5mL), medication price; shipment/duties billed separately
Record

Notes

Recorded against this company rather than one program.

September 2, 2026

  1. 1. NowPatient is a UK company (Infohealth Ltd, GPhC-registered pharmacy) doing business in the US from an Austin, TX office; the site serves a 'United States' region but its own Cancellation & Returns page still quotes EU/UK consumer-contract cancellation law (14-day cooling-off, EU regulations) rather than a US-specific policy — this looks like unlocalized content, flagged rather than silently treated as the US policy. The site sells two separate memberships (Core, $0.00/mo, and Core+, $9.99/mo) that mainly affect free shipping and AI/tool access, not medication price; medication is billed per item, e.g. Mounjaro 'Price $251.98' plus 'Shipment & duties $75.00' unless on Core+, where a $0.00 shipment line appears. So the membership is optional and does not gate access to the drug price. 'Wegovy Injection' and 'Wegovy Tablets' are both sold as separate SKUs; the tablet product's own copy calls it 'Wegovy® Tablets (25 mg)' and 'the first GLP-1 receptor agonist weight-loss medicine available as a tablet' — recorded as 'oral semaglutide' per taxonomy, though whether this exact product is FDA-approved in the US is not stated on the page (one of the site's own blog post titles calls an oral Wegovy pill 'Set to Be Approved by End of 2025', which is inconsistent with the product page selling it now — flagged, not resolved). No specific list of served US states was found on any page checked; prescriber model is a video consultation, i.e. synchronous.

Before you act

Cite this

Treatment Registry. (2026). NowPatient: recorded programs and prices. Last verified September 2, 2026. Retrieved [your access date], from https://treatmentregistry.com/providers/nowpatient